Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 16/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 13/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | GALR3 | O60755 | 1/20 | 0.54 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13806436 | 0.88 | KMT2A (0.58) | KMT2ARAB9ALMNAGALR3NR2F2 | |
| SCHEMBL4281248 | 0.88 | RAB9A (0.55) | EPHX2NR1H4KMT2ARAB9ALMNA | |
| SCHEMBL4281554 | 0.88 | KMT2A (0.54) | EPHX2NR1H4KMT2ARAB9ALMNA | |
| SCHEMBL9527642 | 0.83 | LMNA (0.77) | EPHX2NR1H4KMT2ARAB9ALMNA | |
| SCHEMBL10339786 | 0.81 | EPHX2 (0.54) | EPHX2NR1H4KMT2ARAB9ALMNA | |
| SCHEMBL13806438 | 0.77 | KMT2A (0.54) | KMT2ARAB9ALMNAGALR3NR2F2 | |
| SCHEMBL11938558 | 0.77 | LMNA (0.57) | EPHX2NR1H4KMT2ARAB9ALMNA | |
| SCHEMBL15167081 | 0.76 | KMT2A (0.55) | EPHX2NR1H4KMT2ARAB9ALMNA | |
| SCHEMBL13806437 | 0.75 | LMNA (0.58) | KMT2ARAB9ALMNAGALR3NR2F2 | |
| SCHEMBL11938556 | 0.75 | LMNA (0.58) | EPHX2NR1H4KMT2ARAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | claimed |
| EP-1847531-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-24 | — | — | EP | claimed |
| US-20090156582-A1 | Pyrazole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1847531-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | GSK3B, GSK3A, GSKIP | EPHX2 2232/4885NR1H4 595/4885KMT2A 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.